|
US5703058A
(en)
*
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
|
EP1058686B1
(en)
*
|
1998-02-25 |
2006-11-02 |
Emory University |
2'-fluoronucleosides
|
|
CN1427722A
(zh)
|
2000-02-18 |
2003-07-02 |
希拉生物化学股份有限公司 |
用核苷类似物治疗或预防黄病毒感染的方法
|
|
EP1964569A3
(en)
|
2000-04-13 |
2009-07-22 |
Pharmasset, Inc. |
3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
|
|
PY0111577A
(es)
*
|
2000-05-23 |
2017-01-02 |
Idenix Cayman Ltd |
Métodos y composiciones para el tratamiento del virus de la hepatitis c
|
|
AP2006003708A0
(en)
*
|
2000-05-26 |
2006-08-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flavivirusesand pestiviruses
|
|
FR2810319A1
(fr)
*
|
2000-06-15 |
2001-12-21 |
Ppg Sipsy |
Composes alpha-phenylsulfinyl-alpha-halogeno-butyrolactone et halogeno-2-buten-2-olide-4 utiles pour la preparation de composes halogeno-2-oxymethyl-4-furanone (4h)
|
|
US20030008841A1
(en)
*
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
|
JP2004533406A
(ja)
*
|
2000-10-18 |
2004-11-04 |
フアーマセツト・リミテツド |
ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
|
|
US7105499B2
(en)
*
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
SI1355916T1
(sl)
*
|
2001-01-22 |
2007-04-30 |
Merck & Co Inc |
Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
|
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
AU2002242096A1
(en)
*
|
2001-02-06 |
2002-08-19 |
The University Of Georgia Research Foundation, Inc. |
Novel compounds and methods for inhibiting/treating hiv infections and aids related symptoms
|
|
CN1505635A
(zh)
|
2001-03-01 |
2004-06-16 |
|
2′,3′-二脱氧-2＇,3＇-二脱氢核苷的合成方法
|
|
WO2002069903A2
(en)
*
|
2001-03-06 |
2002-09-12 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
|
GB0114286D0
(en)
*
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
|
US6949522B2
(en)
|
2001-06-22 |
2005-09-27 |
Pharmasset, Inc. |
β-2′- or 3′-halonucleosides
|
|
AU2002330154A1
(en)
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
|
US7049303B2
(en)
|
2001-11-07 |
2006-05-23 |
Medical Research Council |
Inhibition of viruses
|
|
EP1569652A4
(en)
|
2001-12-14 |
2008-07-02 |
Pharmasset Inc |
NUCLEOSIDES N SP 4 / SP-ACYLCYTOSINES FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
WO2003068162A2
(en)
*
|
2002-02-14 |
2003-08-21 |
Pharmasset Ltd. |
Modified fluorinated nucleoside analogues
|
|
CN1678326A
(zh)
*
|
2002-06-28 |
2005-10-05 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
CN101172993A
(zh)
*
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
PT1523489E
(pt)
*
|
2002-06-28 |
2014-06-24 |
Centre Nat Rech Scient |
Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
|
|
US20040067877A1
(en)
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
|
JP2006507235A
(ja)
|
2002-08-01 |
2006-03-02 |
フアーマセツト・インコーポレイテツド |
フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物
|
|
US6884880B2
(en)
*
|
2002-08-21 |
2005-04-26 |
Ash Stevens, Inc. |
Process for the preparation of 9-β-anomeric nucleoside analogs
|
|
US7902203B2
(en)
*
|
2002-11-01 |
2011-03-08 |
Abbott Laboratories, Inc. |
Anti-infective agents
|
|
RU2005118421A
(ru)
|
2002-11-15 |
2006-01-20 |
Айденикс (Кайман) Лимитед (Ky) |
2'-разветвленные нуклеозиды и мутация flaviviridae
|
|
PL377287A1
(pl)
*
|
2002-12-12 |
2006-01-23 |
Idenix (Cayman) Limited |
Sposób wytwarzania 2'-rozgałęzionych nukleozydów
|
|
RU2005123395A
(ru)
*
|
2002-12-23 |
2006-01-27 |
Айденикс (Кайман) Лимитед (Ky) |
Способ получения 3-нуклеозидных пролекарств
|
|
WO2004084796A2
(en)
*
|
2003-03-28 |
2004-10-07 |
Pharmasset Ltd. |
Compounds for the treatment of flaviviridae infections
|
|
US7595390B2
(en)
*
|
2003-04-28 |
2009-09-29 |
Novartis Ag |
Industrially scalable nucleoside synthesis
|
|
BRPI0419345B8
(pt)
*
|
2003-05-30 |
2021-05-25 |
Gilead Pharmasset Llc |
uso do (2r)-2-desoxi-2-flúor-2-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
|
|
RU2361875C2
(ru)
|
2003-06-30 |
2009-07-20 |
Айденикс (Кайман) Лимитед |
СИНТЕЗ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
|
|
DK1658302T3
(da)
*
|
2003-07-25 |
2010-11-22 |
Idenix Pharmaceuticals Inc |
Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
|
|
WO2005018330A1
(en)
*
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
|
KR20060123707A
(ko)
|
2003-08-27 |
2006-12-04 |
바이오타, 인코포레이티드 |
치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드
|
|
WO2005026186A1
(de)
*
|
2003-09-12 |
2005-03-24 |
Max-Delbrück-Centrum für Molekulare Medizin |
Β-l-nucleoside und ihre verwendung als pharmazeutische mittel zur behandlung viraler erkrankungen
|
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
|
US7405220B2
(en)
*
|
2004-06-09 |
2008-07-29 |
Hoffmann-La Roche Inc. |
Pyrazolopyrimidines
|
|
KR100839394B1
(ko)
*
|
2004-06-09 |
2008-06-20 |
에프. 호프만-라 로슈 아게 |
피라졸로 피리미딘
|
|
US7534767B2
(en)
|
2004-06-15 |
2009-05-19 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
|
|
WO2006000922A2
(en)
*
|
2004-06-23 |
2006-01-05 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
|
CA2571079A1
(en)
|
2004-06-24 |
2006-02-02 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
DE602005015466D1
(de)
*
|
2004-08-23 |
2009-08-27 |
Hoffmann La Roche |
Antivirale 4'-azidonucleoside
|
|
MX2007003085A
(es)
|
2004-09-14 |
2007-08-02 |
Pharmasset Inc |
Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
|
|
WO2006093801A1
(en)
*
|
2005-02-25 |
2006-09-08 |
Abbott Laboratories |
Thiadiazine derivatives useful as anti-infective agents
|
|
US7524831B2
(en)
*
|
2005-03-02 |
2009-04-28 |
Schering Corporation |
Treatments for Flaviviridae virus infection
|
|
EP1858889A1
(en)
|
2005-03-08 |
2007-11-28 |
Biota Scientific Management Pty. Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
|
JP4516863B2
(ja)
*
|
2005-03-11 |
2010-08-04 |
株式会社ケンウッド |
音声合成装置、音声合成方法及びプログラム
|
|
WO2006119061A2
(en)
|
2005-05-02 |
2006-11-09 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
|
TWI387603B
(zh)
|
2005-07-20 |
2013-03-01 |
Merck Sharp & Dohme |
Ｈｃｖ ｎｓ３蛋白酶抑制劑
|
|
KR20080036598A
(ko)
|
2005-08-01 |
2008-04-28 |
머크 앤드 캄파니 인코포레이티드 |
Ｈｃｖ ｎｓ３ 프로테아제 억제제로서의 마크로사이클릭펩티드
|
|
US7705009B2
(en)
*
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
|
AU2006324098C1
(en)
|
2005-12-09 |
2011-12-08 |
F. Hoffmann-La Roche Ag |
Antiviral nucleosides
|
|
US7915411B2
(en)
|
2005-12-21 |
2011-03-29 |
Abbott Laboratories |
Anti-viral compounds
|
|
EP2345652A1
(en)
|
2005-12-21 |
2011-07-20 |
Abbott Laboratories |
Antiviral compounds
|
|
US7910595B2
(en)
*
|
2005-12-21 |
2011-03-22 |
Abbott Laboratories |
Anti-viral compounds
|
|
CN102702194A
(zh)
|
2005-12-21 |
2012-10-03 |
雅培制药有限公司 |
抗病毒化合物
|
|
JP5254033B2
(ja)
*
|
2005-12-23 |
2013-08-07 |
イデニク プハルマセウティカルス，インコーポレイテッド |
分岐型ヌクレオシドを調製するための合成中間体の製造方法
|
|
KR101237312B1
(ko)
*
|
2006-02-10 |
2013-03-04 |
삼진제약주식회사 |
피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물
|
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
|
US9644039B2
(en)
|
2006-03-24 |
2017-05-09 |
The Regents Of The University Of California |
Acid-degradable and bioerodible modified polyhydroxylated materials
|
|
WO2010005847A1
(en)
*
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Acid-degradable and bioerodible modified polyhydroxylated materials
|
|
CA2643680A1
(en)
|
2006-04-11 |
2007-11-22 |
Novartis Ag |
Hcv/hiv inhibitors and their uses
|
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
US7662958B2
(en)
*
|
2006-07-19 |
2010-02-16 |
Rolf Wagner |
Anti-infective agents
|
|
US20090298708A1
(en)
*
|
2006-08-23 |
2009-12-03 |
Masad Damha J |
2'-deoxy-2'-fluoro-beta-d-arabinonucleoside 5'-triphosphates and their use in enzymatic nucleic acid synthesis
|
|
MX2009003452A
(es)
*
|
2006-10-10 |
2009-04-14 |
Medivir Ab |
Inhibidores nucleosidicos del vhc.
|
|
PL2084174T3
(pl)
*
|
2006-10-10 |
2013-12-31 |
Gilead Pharmasset Llc |
Sposób otrzymywania nukleozydów rybofuranozylopirymidynowych
|
|
EP2079479B1
(en)
|
2006-10-24 |
2014-11-26 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
|
AU2007309488B2
(en)
|
2006-10-24 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
CA2667031C
(en)
|
2006-10-27 |
2013-01-22 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
|
CN101568346B
(zh)
|
2006-10-27 |
2015-11-25 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
CA2672250C
(en)
|
2006-12-20 |
2013-04-30 |
Ian Stansfield |
Antiviral indoles
|
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
US8236950B2
(en)
*
|
2006-12-20 |
2012-08-07 |
Abbott Laboratories |
Anti-viral compounds
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
US8071568B2
(en)
|
2007-01-05 |
2011-12-06 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
|
BRPI0808089A2
(pt)
|
2007-02-28 |
2014-07-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
|
|
EP2124553B1
(en)
*
|
2007-03-23 |
2017-03-01 |
Southern Research Institute |
Method for treating and preventing arthritis
|
|
US7964580B2
(en)
*
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
CN100532388C
(zh)
*
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
|
JP2010533699A
(ja)
|
2007-07-17 |
2010-10-28 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
Ｃ型肝炎感染症の治療のための大環状インドール誘導体
|
|
AU2008277377B2
(en)
|
2007-07-19 |
2013-08-01 |
Msd Italia S.R.L. |
Macrocyclic compounds as antiviral agents
|
|
WO2009058800A2
(en)
*
|
2007-10-29 |
2009-05-07 |
President And Fellows Of Harvard College |
Synthesis of nucleosides
|
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
EP2271345B1
(en)
|
2008-04-28 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
US20090274686A1
(en)
*
|
2008-05-02 |
2009-11-05 |
Yat Sun Or |
Nucleoside phosphonate derivatives
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
WO2010014134A1
(en)
|
2008-07-02 |
2010-02-04 |
Idenix Pharamaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
|
ME02024B
(me)
|
2008-07-22 |
2015-05-20 |
Merck Sharp & Dohme |
Makrociklična jedinjenja hinoksalina kao inhibitori hcv ns3 proteaze
|
|
TW201026715A
(en)
|
2008-12-23 |
2010-07-16 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
|
JP6104504B2
(ja)
|
2008-12-23 |
2017-03-29 |
ギリアド ファーマセット エルエルシー |
ヌクレオシド類似体
|
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス，インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
|
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
|
BRPI1010809A2
(pt)
*
|
2009-05-12 |
2015-10-13 |
Southern Res Inst |
composto, composição farmacêutica, métodos de tratar câncer em mamífero e usos de compostos e de composição farmacêutica
|
|
CN102458444A
(zh)
|
2009-05-13 |
2012-05-16 |
英安塔制药有限公司 |
用作丙型肝炎病毒抑制剂的大环化合物
|
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
WO2011014487A1
(en)
|
2009-07-30 |
2011-02-03 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
|
BR112012011221A2
(pt)
|
2009-11-14 |
2016-04-05 |
Hoffmann La Roche |
biomarcadores para prever resposta rápida ao tratamento de hcv
|
|
US9700560B2
(en)
|
2009-11-16 |
2017-07-11 |
University Of Georgia Research Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
US8816074B2
(en)
*
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
|
CN102656459A
(zh)
|
2009-12-02 |
2012-09-05 |
弗·哈夫曼-拉罗切有限公司 |
用于预测对hcv治疗持续应答的生物标志物
|
|
SG181797A1
(en)
|
2009-12-18 |
2012-07-30 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
CL2011000716A1
(es)
|
2010-03-31 |
2012-04-20 |
Gilead Pharmasset Llc |
Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
|
|
TWI515000B
(zh)
|
2010-04-01 |
2016-01-01 |
伊迪尼克製藥公司 |
用於治療病毒感染之化合物及醫藥組合物
|
|
US9284188B2
(en)
|
2010-09-03 |
2016-03-15 |
The Regents Of The University Of California |
Cytosolic delivery of materials with endosome-disrupting colloids
|
|
HUE028384T2
(en)
|
2010-09-21 |
2016-12-28 |
Enanta Pharm Inc |
Macrocyclic proline derived hcv serine protease inhibitors
|
|
EP2624826B1
(en)
|
2010-10-08 |
2018-07-18 |
Novartis AG |
Vitamin e formulations of sulfamide ns3 inhibitors
|
|
WO2012075140A1
(en)
|
2010-11-30 |
2012-06-07 |
Pharmasset, Inc. |
Compounds
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
|
CN103842369A
(zh)
|
2011-03-31 |
2014-06-04 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
JP2014511875A
(ja)
|
2011-04-13 |
2014-05-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
２’−シアノ置換ヌクレオシド誘導体およびウイルス疾患の治療のためのその使用方法
|
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
EP2696681B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
US9416154B2
(en)
|
2011-07-13 |
2016-08-16 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
WO2013009737A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
|
SI2709613T2
(sl)
|
2011-09-16 |
2020-12-31 |
Gilead Pharmasset LLC c/o Gilead Sciences, Inc. |
Postopki za zdravljenje HCV
|
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
|
|
US20140286903A1
(en)
*
|
2011-11-10 |
2014-09-25 |
Inhibitex, Inc. |
Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections
|
|
WO2013074386A2
(en)
|
2011-11-15 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
CA3131037A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
|
AU2013221571A1
(en)
|
2012-02-14 |
2014-08-28 |
University Of Georgia Research Foundation, Inc. |
Spiro [2.4] heptanes for treatment of Flaviviridae infections
|
|
AP3913A
(en)
|
2012-05-22 |
2016-11-26 |
Idenix Pharamaceuticals Inc |
D-amino acid compounds for liver disease
|
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
HUE029038T2
(en)
|
2012-05-25 |
2017-01-30 |
Janssen Sciences Ireland Uc |
Uracil spirooxetan nucleosides
|
|
WO2014052638A1
(en)
|
2012-09-27 |
2014-04-03 |
Idenix Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
|
WO2014049540A2
(en)
|
2012-09-29 |
2014-04-03 |
Novartis Ag |
Cyclic peptides and use as medicines
|
|
SG11201502750UA
(en)
|
2012-10-08 |
2015-06-29 |
Idenix Pharmaceuticals Inc |
2'-chloro nucleoside analogs for hcv infection
|
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
|
EP2909222B1
(en)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
2',4'-bridged nucleosides for hcv infection
|
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
|
EP2920195A1
(en)
|
2012-11-14 |
2015-09-23 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
GEP201706757B
(en)
|
2012-12-21 |
2017-10-25 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
|
NZ729172A
(en)
|
2013-01-31 |
2018-06-29 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
EP2970357B1
(en)
|
2013-03-13 |
2025-01-01 |
Idenix Pharmaceuticals LLC |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
JP2016529293A
(ja)
|
2013-08-27 |
2016-09-23 |
ギリアド ファーマセット エルエルシー |
２つの抗ウイルス化合物の組合せ製剤
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
US10351918B2
(en)
|
2013-10-30 |
2019-07-16 |
Green Life Biotech, Llc |
Pathogenesis quantification systems and treatment methods for citrus greening blight
|
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
|
WO2015134561A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
CN106687118A
(zh)
|
2014-07-02 |
2017-05-17 |
配体药物公司 |
前药化合物及其用途
|
|
GEP20217282B
(en)
|
2015-03-06 |
2021-08-10 |
Atea Pharmaceuticals Inc |
β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
|
|
MX2018002707A
(es)
|
2015-09-02 |
2018-08-01 |
Abbvie Inc |
Derivados de tetrahidrofurano antivirales.
|
|
US10202412B2
(en)
|
2016-07-08 |
2019-02-12 |
Atea Pharmaceuticals, Inc. |
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
|
|
WO2018013937A1
(en)
|
2016-07-14 |
2018-01-18 |
Atea Pharmaceuticals, Inc. |
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
|
|
PT3512863T
(pt)
|
2016-09-07 |
2022-03-09 |
Atea Pharmaceuticals Inc |
Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
|
|
WO2018109666A1
(en)
|
2016-12-15 |
2018-06-21 |
Nestec Sa |
Compositions and methods that modulate cholesterol in a companion animal
|
|
EP3554258B1
(en)
|
2016-12-15 |
2023-07-19 |
Société des Produits Nestlé S.A. |
Compositions and methods that modulate phosphorus or enzymes in a companion animal
|
|
CN110248951B
(zh)
|
2017-02-01 |
2022-10-28 |
阿堤亚制药公司 |
用于治疗丙型肝炎病毒的核苷酸半硫酸盐
|
|
EP3661937B1
(en)
|
2017-08-01 |
2021-07-28 |
Gilead Sciences, Inc. |
Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
|
|
CN111788196A
(zh)
|
2018-01-09 |
2020-10-16 |
配体药物公司 |
缩醛化合物及其治疗用途
|
|
WO2019200005A1
(en)
|
2018-04-10 |
2019-10-17 |
Atea Pharmaceuticals, Inc. |
Treatment of hcv infected patients with cirrhosis
|
|
JP7496132B2
(ja)
*
|
2018-08-31 |
2024-06-06 |
国立大学法人 鹿児島大学 |
核酸アナログ及び抗ｂ型肝炎ウイルス剤
|
|
US20220099637A1
(en)
|
2018-12-04 |
2022-03-31 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
|
US20240261317A1
(en)
*
|
2021-05-17 |
2024-08-08 |
Rome Therapeutics, Inc. |
Methods of treating medical conditions and inhibiting line1 reverse transcriptaseusing a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compound
|
|
BR112023026356A2
(pt)
|
2021-06-17 |
2024-03-05 |
Atea Pharmaceuticals Inc |
Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
|